Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06 2023 - 7:05AM
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that Sath Shukla, President and Chief
Executive Officer of Spero Therapeutics, will present and be
available for one-on-one meetings at the H.C. Wainwright 25th
Annual Global Investment Conference, which is taking place
September 11-13, 2023, at the Lotte New York Palace Hotel in New
York, NY. Details are as follows:
H.C. Wainwright
25th Annual Global Investment
Conference Corporate Presentation:
Tuesday, September 12, 2023, from 11:30 AM-12:00 PM ET
Webcast Link:
https://journey.ct.events/view/7d04fb43-ff26-406f-9676-dc4aa23e674d
The webcast may also be accessed through Spero
Therapeutics’ website (www.sperotherapeutics.com) on the “Events
and Presentations” page under the “Connect” tab. Replays will be
available on the website following the conclusion of each
event.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not
FDA-approved.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Forward Looking StatementsThis press release
may contain forward-looking statements. These statements include,
but are not limited to, statements about the design, initiation,
timing, progress and results of Spero's preclinical studies and
clinical trials and its research and development programs, as well
as the regulatory path forward for tebipenem HBr and potential FDA
approval, the potential commercialization of tebipenem HBr and its
future value, the potential receipt of milestone payments and
royalties on future sales under the GSK license agreement, and
Spero’s cash runway. In some cases, forward-looking statements can
be identified by terms such as "may," "will," "should," "expect,"
"plan," "aim," "anticipate," "could," "intent," "target,"
"project," "contemplate," "believe," "estimate," "predict,"
"potential" or "continue" or the negative of these terms or other
similar expressions. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including whether tebipenem HBr, SPR720
and SPR206 will advance through the clinical trial process on a
timely basis, or at all, taking into account the effects of
possible regulatory delays, slower than anticipated patient
enrollment, manufacturing challenges, clinical trial design and
clinical outcomes; whether the results of such trials will warrant
submission for approval from the FDA or equivalent foreign
regulatory agencies; whether the FDA will ultimately approve
tebipenem HBr and, if so, the timing of any such approval; whether
the FDA will require any additional clinical data or place labeling
restrictions on the use of tebipenem HBr that would delay approval
and/or reduce the commercial prospects of tebipenem HBr; whether a
successful commercial launch can be achieved and market acceptance
of tebipenem HBr can be established; whether results obtained in
preclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; Spero's reliance on
third parties to manufacture, develop, and commercialize its
product candidates, if approved; Spero’s need for additional
funding; the ability to commercialize Spero's product candidates,
if approved; Spero's ability to retain key personnel; Spero’s
ongoing leadership transitions; whether Spero's cash resources will
be sufficient to fund its continuing operations for the periods
and/or trials anticipated; and other factors discussed in the "Risk
Factors" set forth in filings that Spero periodically makes with
the SEC. The forward-looking statements included in this press
release represent Spero's views as of the date of this press
release. Spero anticipates that subsequent events and developments
will cause its views to change. However, while Spero may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spero's views as of any date subsequent to the date of
this press release.
Investor Relations Contact: Ted
JenkinsVice President, Head of Investor
RelationsTjenkins@sperotherapeutics.com (617) 798-4039
Media Inquiries: Lora Grassilli, Health Media
RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2024 to May 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From May 2023 to May 2024